What is Petros Pharmaceuticals Earnings Power Value (EPV)?
As of Mar24, Petros Pharmaceuticals's earnings power value is $0.64. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Petros Pharmaceuticals Earnings Power Value (EPV) Historical Data
The historical data trend for Petros Pharmaceuticals's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals Earnings Power Value (EPV) Chart
|
Petros Pharmaceuticals Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
- |
|
Petros Pharmaceuticals Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Petros Pharmaceuticals's Earnings Power Value (EPV)
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Earnings Power Value (EPV) falls into.
Petros Pharmaceuticals Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
| Wayne Remell Walker |
director |
1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103 |
| Greg Bradley |
director |
200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
| John D Shulman |
director, 10 percent owner |
|
| Jcp Iii Sm Aiv, L.p. |
10 percent owner |
5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
| Juggernaut Partners Iii Gp, L.p. |
10 percent owner |
5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
| Juggernaut Partners Iii Gp, Ltd. |
10 percent owner |
5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
| Metp Holdings Llc |
10 percent owner |
5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
| Joshua Silverman |
director |
IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
| Bruce Bernstein |
director |
780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017 |
| Keith Lavan |
officer: Chief Financial Officer |
200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
| Fady Boctor |
officer: Pres. & Chief Comm. Officer |
200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
| Andrew Gesek |
officer: President, Timm Medical |
200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
| Metuchen Therapeutics, Llc |
10 percent owner |
5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
| Mitchell Arnold |
officer: Prin. Acct. Off/Prin. Fin. Off |
200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726 |
Petros Pharmaceuticals (Petros Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTPI has been successfully added to your